A small change in a peptide sequence can matter. One frequently cited hair-follicle experiment studied AHK-copper, not GHK-copper. The researchers examined isolated human follicles and dermal papilla cells in vitro. AHK-copper and human hair follicles in vitro That distinction should remain visible whenever the study is discussed.

Human tissue outside the body is valuable for investigating biology, but it is not a clinical trial of hair regrowth. A follicle in culture does not reproduce the complete scalp environment, the causes of a person's hair loss or the long-term exposure to a finished product.

A defensible GHK-copper claim would therefore need evidence on GHK-copper itself and on the relevant formulation. Data for a related copper complex can generate a hypothesis, but cannot silently replace that evidence. Nor does a topical experiment establish an effect from systemic administration.

Clinical research should identify the condition being treated. Pattern hair loss, inflammatory scalp disease and temporary shedding are different problems. Appropriate outcomes might include standardized hair counts, shaft measurements, photographs and patient-relevant change over a meaningful period. A before-and-after image without controlled lighting or a comparison group can be misleading.

Safety and tolerability also belong in the assessment, including irritation and treatment discontinuation. A biological response in an isolated follicle does not establish that a commercial product is harmless or preferable to established care.

This article does not recommend a copper-peptide hair product. It highlights a source-identification error that can distort an entire claim: substituting one closely named molecule for another. Specialist review should confirm the exact sequence, study model, diagnosis and finished-product evidence before any statement about treating hair loss is published.